|
So, you really are an angel! Thank you for posting this.
If I understand it correctly, if one is over age 45, and Her2+/ER+, it is less likely that one would also be PR+. This may explain the fact that Tamox is less effective for Her2 patients than AIs-- AIs are most effective (vs. Tamox) in patients that are ER+ and PR- (if I'm remembering correctly). So if breast cancer typically affects older women, and older women are more likely to be ER+ and PR- when also Her2+, I can see why the data regarding Her2 and the efficacy of Tamox vs. AIs looks as it does, on the surface. So in my case, being that I'm highly ER+/PR+, I have less reason to believe that AIs would be superior.
Phew! That took a lot out of me. (Now I need some chocolate.)
Do you think I have it correct?
Thanks everyone for your posts to this question.
Jen
__________________
dx 4/05 @ 34 y.o.
Stage IIIC, ER+ (90%)/PR+ (95%)/HER2+ (IHC 3+)
lumpectomy-- 2.5 cm 15+/37 nodes
(IVF in between surgery and chemo)
tx dd A/C, followed by dd Taxol & Herceptin
30 rads (or was it 35?)
Finished Herceptin on 7/24/06
Tamox
livingcured.blogspot.com
"Keep your face to the sunshine and you cannot see the shadow." -- Helen Keller
|